Laboratory testing of EmitBio’s proprietary light technology has shown the system to be effective in deactivating multiple coronaviruses, beyond the SARS-CoV-2 virus that causes Covid-19. This includes the highly fatal Middle East Respiratory Syndrome coronavirus (MERS-CoV). The findings also indicate that the technology is likely to be effective against SARS-CoV-2 variants.
Canadian biotechnology company Precision Biomonitoring has announced that it has received approval from Health Canada for its TRIPLELOCK SARS-CoV-2 test in the 96-Well Plate format. The approval makes the ready-to-use, stable, and scalable kit for the detection of the SARS-CoV-2 virus available for immediate use in laboratories across Canada.
UK-headquartered diagnostics firm Oxford Immunotec has announced an update to the configuration of the T-SPOT Discovery SARS-CoV-2 kit. The kit is currently in its research stages and has been updated using the company’s expertise in T cell response to the SARS-CoV-2 virus.